Barclays Cuts Ionis Pharmaceuticals Price Target to $70 From $85
Barclays maintained its Overweight rating on Ionis Pharmaceuticals while lowering its price target from $85 to $70.
Related stories
Nearly 3,900 Flights Canceled After FAA Groundstop, Over 2,300 Delayed
The FAA groundstop ended after four hours, but airlines continued to face disruptions on Saturday, with nearly 3,900 flights canceled and more than 2,300 delayed.
M impact | EQUITY | Nov 14, 2026, 03:52 PM UTC
Thousands of US Flights Canceled or Delayed as System Recovers
Thousands of US flights were canceled or delayed as air travel recovered from a shutdown.
M impact | EQUITY | Nov 14, 2026, 03:50 PM UTC
Mercedes-Benz Freezes New Investment in Germany, Considers Factory Closures
Mercedes-Benz has frozen new investment in Germany and put factory closures on the table, as costs deepen. The report cites a 31% Q3 2026 decline in China sales and a full-year pas
M impact | EQUITY | Nov 14, 2026, 03:01 PM UTC
MSC Nears Deal to Acquire 80% Stake in Meyer Werft, Spiegel Reports
The German government and Lower Saxony are nearing a deal giving Geneva-based shipping group MSC the right to acquire about 80% of the German shipbuilder's shares, Spiegel reported
M impact | EQUITY | Nov 14, 2026, 12:11 PM UTC
Advanta Agrees to Acquire Hytech Egypt Holding Company
Advanta entered into an agreement on Aug. 15, 2026, to acquire Hytech Egypt USA LLC, the holding company of Misr Hytech Seed International, from Helios Investment Partners and The
M impact | EQUITY | Nov 14, 2026, 11:51 AM UTC
Microsoft Restores Microsoft 365 After Global Outage
Microsoft said it restored Microsoft 365 services after a global outage disrupted Outlook, Teams and other applications for more than 24 hours. The company said the disruption was
M impact | EQUITY | Nov 14, 2026, 10:41 AM UTC